{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:05:21Z","timestamp":1778313921125,"version":"3.51.4"},"reference-count":50,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T00:00:00Z","timestamp":1490918400000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin &amp; Trans Imm"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:p>Influenza A viruses are important human and animal pathogens. Seasonal influenza viruses cause infections every year, and occasionally zoonotic viruses emerge to cause pandemics with significantly higher morbidity and mortality rates. Three cases of laboratory confirmed human infection with avian influenza A (H7N9) virus were reported in 2013, and there have been several cases reported across South East Asia, and recently in North America. Most patients experience severe respiratory illness, with mortality rates approaching 40%. No vaccine is currently available and the use of antivirals is complicated due to the emergence of drug resistant strains. Thus, there is a need to identify new drugs for therapeutic intervention and disease control. In humans, following H7N9 infection, there is excessive expression of pro\u2010inflammatory factors CCL2, IL\u20106, IL\u20108, IFN\u03b1, interferon\u2010\u03b3, IP\u201010, MIG and macrophage inflammatory protein\u20101\u03b2, which has been shown to contribute to fatal disease outcomes in mouse models of infection. In the current study, the potent inhibitor of CCL2 synthesis, Bindarit, was examined as a countermeasure for H7N9\u2010induced inflammation in a mouse model. Bindarit treatment of mice did not have any substantial therapeutic efficacy in H7N9 infection. Consequently, the results suggest that Bindarit may be ill\u2010advised in the treatment of influenza H7N9 infection.<\/jats:p>","DOI":"10.1038\/cti.2017.8","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T07:22:17Z","timestamp":1490944937000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeting the pro\u2010inflammatory factor CCL2 (MCP\u20101) with Bindarit for influenza A (H7N9) treatment"],"prefix":"10.1002","volume":"6","author":[{"given":"Stefan","family":"Wolf","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, University of Georgia  Athens GA USA"},{"name":"Institute for Glycomics, Griffith University, Gold Coast Campus  Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Georgia  Athens GA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Perwitasari","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Georgia  Athens GA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Mahalingam","sequence":"additional","affiliation":[{"name":"Institute for Glycomics, Griffith University, Gold Coast Campus  Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph A","family":"Tripp","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Georgia  Athens GA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,31]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304459"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12379"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304617"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1321748111"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2015.1006198"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f4752"},{"key":"e_1_2_7_8_2","unstructured":"CDC.Avian Influenza A (H7N9) Virus 2014 (e\u2010pub ahead of print). Available at:https:\/\/www.cdc.gov\/flu\/avianflu\/h7n9\u2010virus.htm."},{"key":"e_1_2_7_9_2","unstructured":"Canada Go.Government of Canada and British Columbia confirm additional case of H7N9 avian influenza in Canada 2015 [e\u2010pub ahead of print]. Available at:http:\/\/www.phac\u2010aspc.gc.ca\/eri\u2010ire\/h7n9\/risk_assessment\u2010evaluation_risque\u2010eng.php."},{"key":"e_1_2_7_10_2","first-page":"64","article-title":"Changes in and shortcomings of control strategies, drug stockpiles, and vaccine development during outbreaks of avian influenza A H5N1, H1N1, and H7N9 among humans","volume":"7","author":"Mei L","year":"2013","journal-title":"Biosci Trends"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161207782794248"},{"key":"e_1_2_7_12_2","first-page":"CD001169","article-title":"Amantadine and rimantadine for influenza A in adults","volume":"19","author":"Jefferson T","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e3283199797"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2174\/138955751410141020150822","article-title":"Viral M2 ion channel protein: a promising target for anti\u2010influenza drug discovery","volume":"14","author":"Moorthy NSF","year":"2014","journal-title":"Mini Rev Med Chem"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu447"},{"key":"e_1_2_7_16_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1155\/2006\/106989","article-title":"Ode to oseltamivir and amantadine?","volume":"17","author":"Conly J","year":"2006","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202441"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092987"},{"key":"e_1_2_7_19_2","first-page":"119","article-title":"Impact of the anti\u2010inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins","volume":"19","author":"Mirolo M","year":"2008","journal-title":"Eur Cytokine Netw"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24682"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir470"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02034-14"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1044-5323(02)00125-2"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3863-05.2006"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(99)00048-X"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152710791011982"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.WCB.0000071885.63724.20"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-6-40"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2008.07.003"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2008.05.016"},{"key":"e_1_2_7_32_2","first-page":"6","article-title":"Antivirals: Bindarit\u2014the future in alphavirus treatment","volume":"5","author":"Herrero L","year":"2013","journal-title":"J Antivir Antiretrovir"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2009.0084"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201141676"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2010.0123"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.2174\/138945011701151217110917"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00000301"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-171"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-012-9473-5"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/298326"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03364-13"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2008-0423OC"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.08.001"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.4103\/0970-2113.92361"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02030-09"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001616"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/0471729256.mc15g01s3"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot5439"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01532-12"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01774-14"}],"container-title":["Clinical &amp; Translational Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/cti.2017.8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T04:10:02Z","timestamp":1695960602000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1038\/cti.2017.8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1038\/cti.2017.8"],"URL":"https:\/\/doi.org\/10.1038\/cti.2017.8","archive":["Portico"],"relation":{},"ISSN":["2050-0068","2050-0068"],"issn-type":[{"value":"2050-0068","type":"print"},{"value":"2050-0068","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"2016-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e135"}}